System

{{entity:Pharmaceutical Manufacturing Line}} ({{hex:55F73A59}}) — an automated continuous manufacturing line for oral solid dosage (OSD) forms. The concept session established 6 operating modes, 7 hazards, and 8 stakeholders. This session opens the decomposition phase: 13 STK and 12 SYS requirements scaffolded, 8 subsystems classified and mapped, full decomposition diagram rendered, and baseline Scaffold-2026-03-25 created. At session close: 25 requirements, 12 trace links, 2 diagrams.

Stakeholder Requirements

Thirteen STK requirements were derived from the ConOps stakeholders and scenarios. The {{entity:Patient receiving manufactured medication}} ({{hex:00000011}}) drives the terminal quality gate: {{stk:REQ-SEPHARMAMANUFACTURING-013}} mandates pharmacopoeial compliance across 100% of released batches — AV ≤ 15.0 on L1 content uniformity sampling, potency 98–102% label claim. The {{entity:FDA/EMA Regulatory Inspector}} ({{hex:77c37965}}) anchors two requirements: {{stk:REQ-SEPHARMAMANUFACTURING-002}} (21 CFR Part 11 and EU Annex 11 electronic batch records with complete audit trail) and {{stk:REQ-SEPHARMAMANUFACTURING-006}} (GMP Annex 1/15, ICH Q10 compliance). Operational safety is covered by {{stk:REQ-SEPHARMAMANUFACTURING-004}} (potent compound containment, OEL < 1 µg/m³, breathing zone ≤ 10% OEL) and {{stk:REQ-SEPHARMAMANUFACTURING-005}} (emergency stop ≤ 10 seconds, EN ISO 13850). Commercial viability is established by {{stk:REQ-SEPHARMAMANUFACTURING-001}} (OEE ≥ 75%) and {{stk:REQ-SEPHARMAMANUFACTURING-009}} (degraded production ≥ 50% throughput). Two requirements address supply-chain and regulatory obligations: {{stk:REQ-SEPHARMAMANUFACTURING-008}} (EU FMD/DSCSA serialization within 24 hours) and {{stk:REQ-SEPHARMAMANUFACTURING-010}} (bidirectional batch genealogy, recall response ≤ 4 hours).

System Requirements

Twelve SYS requirements derive directly from the STK tier, each carrying quantified acceptance criteria. {{sys:REQ-SEPHARMAMANUFACTURING-014}} sets the throughput budget: 300,000 tablets per 12-hour shift with hourly OEE reporting by the MES. {{sys:REQ-SEPHARMAMANUFACTURING-016}} quantifies the PAT pipeline: NIR/Raman/laser diffraction sampling at ≤ 30-second intervals, CQA model evaluation within 5 seconds, divert valve actuation within 2 seconds of limit exceedance — total response latency 7 seconds, inside the 10-second acceptable window. {{sys:REQ-SEPHARMAMANUFACTURING-015}} specifies cryptographic hashing on every EBR write and backup intervals ≤ 15 minutes. {{sys:REQ-SEPHARMAMANUFACTURING-017}} sets containment thresholds: 0.5 m/s minimum inward airflow at all access points, alarm at 20% of OEL. {{sys:REQ-SEPHARMAMANUFACTURING-022}} formalises the PAT-degraded fallback: manual 15-minute sampling, ≥ 50% throughput maintained, 30-second supervisor notification. The changeover requirement {{sys:REQ-SEPHARMAMANUFACTURING-021}} enforces TOC ≤ 500 µg/L for rinse water verification and EBR lock that prevents campaign restart prior to electronic sign-off.

Functional Analysis

The production flow is linear across five processing stages, with two cross-cutting control layers. Processing stages: {{entity:Material Handling and Dispensing Subsystem}} ({{hex:56B53A59}}) → {{entity:Granulation and Blending Subsystem}} ({{hex:50F53218}}) → {{entity:Tablet Compression Subsystem}} ({{hex:54E51018}}) → {{entity:Film Coating Subsystem}} ({{hex:56F53218}}) → {{entity:Packaging and Serialisation Subsystem}} ({{hex:54E57258}}). Control layers: {{entity:Process Analytical Technology Subsystem}} ({{hex:55F77A18}}) monitors quality across all processing stages; {{entity:Manufacturing Execution System}} ({{hex:41B77B58}}) orchestrates recipes, batch records, and OEE. A dedicated {{entity:Containment and Environmental Control Subsystem}} ({{hex:55F73858}}) enforces occupational safety and cleanroom integrity across the entire line. The {{trait:System-Essential}} trait appears on MES and PAT — failure of either immediately stops production. The {{trait:Functionally Autonomous}} trait on PAT reflects its independent chemometric decision-making.

Decomposition

flowchart TB
  n0["system - Pharmaceutical Manufacturing Line"]
  n1["subsystem - Material Handling and Dispensing"]
  n2["subsystem - Granulation and Blending"]
  n3["subsystem - Tablet Compression"]
  n4["subsystem - Film Coating"]
  n5["subsystem - Packaging and Serialisation"]
  n6["subsystem - Process Analytical Technology"]
  n7["subsystem - Manufacturing Execution System"]
  n8["subsystem - Containment and Environmental Control"]
  n0 --> n1
  n0 --> n2
  n0 --> n3
  n0 --> n4
  n0 --> n5
  n0 --> n6
  n0 --> n7
  n0 --> n8
  n1 -->|powder| n2
  n2 -->|granules| n3
  n3 -->|tablets| n4
  n4 -->|coated tablets| n5

Next

Priority for the next session is subsystem-level requirements for the two highest-risk subsystems: the {{entity:Process Analytical Technology Subsystem}} (safety-critical diversion function, CQA model integrity, sensor degradation handling) and the {{entity:Manufacturing Execution System}} (21 CFR Part 11 enforcement, LOTO lock-out, EBR write integrity). Interface requirements between PAT and MES are needed first — the CQA diversion path depends on both. The {{entity:Granulation and Blending Subsystem}} carries the highest process hazard (dust explosion, Zone 20/21) and should receive SUB requirements with explicit ATEX classification and explosion-proof instrument specifications in the session following.